Chronically Left Out – Lack of Patient Diversity in Chronic Disease Clinical Trials in Los Angeles

Sunyoung (Stacy) Uhm, BA; Terry Church, DRSc, MA, MS

**BACKGROUND**
49% of Los Angeles County (LAC) population are Hispanic/Latino

1/5 of 167 FDA-approved molecular entities (2008-2013) had differences in exposure and/or responses across racial and ethnic groups

**OBJECTIVE**
To evaluate the lack of diverse representation in clinical trials (CTs) conducted in LAC for chronic diseases, such as CHD, stroke, liver disease, and type 2 diabetes.

**RESULTS**

<table>
<thead>
<tr>
<th>Race</th>
<th>Hispanic/Latino</th>
<th>Asian</th>
<th>NH/PI</th>
<th>Black</th>
<th>White</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary Heart Disease CTs</td>
<td>11.4%</td>
<td>14.0%</td>
<td>0.2%</td>
<td>0.2%</td>
<td>3.2%</td>
<td>5.6%</td>
</tr>
<tr>
<td>Stroke CTs</td>
<td>38.2%</td>
<td>8.8%</td>
<td>0.2%</td>
<td>0.2%</td>
<td>5.2%</td>
<td>7.2%</td>
</tr>
<tr>
<td>Liver Disease CTs</td>
<td>5.2%</td>
<td>3.2%</td>
<td>5.8%</td>
<td>7.2%</td>
<td>0.3%</td>
<td>0.7%</td>
</tr>
<tr>
<td>Type 2 Diabetes CTs</td>
<td>14.0%</td>
<td>1.8%</td>
<td>1.4%</td>
<td>2.2%</td>
<td>1.2%</td>
<td>1.3%</td>
</tr>
</tbody>
</table>

Figure 1. Breakdown by race of participants from 118 coronary heart disease (red), 70 stroke (yellow), 196 liver disease (green), and 170 type 2 diabetes (black) clinical trials that referenced race conducted in LAC. n=601,221 participants

**RESULTS (CONT.)**

- Across all four therapeutic areas, the most prevalent race was White, then Asian followed by Black
- The least represented race was NH/PI (0.2%-0.3%)
- Liver disease CTs had the smallest percentage of White participants

**CONCLUSIONS**
Participants of CTs conducted in LAC for CHD, stroke, liver disease, and type 2 diabetes are not representative of patient populations, which can limit specialized medical therapies.

**REFERENCES**
1. Los Angeles County Department of Public Health

**CONTACT INFO**
1. Stacy Uhm, Psychology B.A. sunyounu@usc.edu
2. Terry Church, DRSc, MA, MS, Department of Regulatory and Quality Sciences tdchurch@usc.edu